GLP-1 & Fertility: What to Know
The surprise pregnancy phenomenon
A growing number of women report unexpected pregnancies while taking GLP-1 medications — sometimes after years of infertility. This has sparked both hope and concern. Understanding the relationship between GLP-1 treatment, weight loss, and fertility helps you make informed decisions about contraception and family planning.
How weight loss affects female fertility
Obesity impairs fertility through several mechanisms: hormonal disruption (excess estrogen from fat tissue), insulin resistance affecting ovulation, and inflammation affecting egg quality and implantation. Weight loss — regardless of method — improves these factors. For women with obesity-related infertility, particularly those with PCOS, even modest weight loss (5-10% of body weight) can restore ovulation and increase pregnancy rates. This is not a GLP-1 effect — it is a weight loss effect — but GLP-1 medications produce weight loss that is often substantial enough to trigger fertility improvement.
The critical safety rule
GLP-1 medications are contraindicated during pregnancy. Weight loss is not recommended during pregnancy and may cause fetal harm. If you are sexually active and not actively planning pregnancy, reliable contraception is essential. If you become pregnant while taking GLP-1 medication, stop the medication immediately and contact your provider.
Planning pregnancy around GLP-1 treatment
If you are planning pregnancy, discuss timing with your provider. General guidance: discontinue GLP-1 at least 1-2 months before attempting conception to allow the medication to clear your system. Use this transition period to establish sustainable nutrition and activity habits that support a healthy pregnancy. Continue folic acid or prenatal vitamin supplementation. Some providers may recommend achieving a stable weight on GLP-1 before discontinuing for pregnancy, since active weight loss is not recommended during pregnancy.
Male fertility considerations
Human data on GLP-1 medications and male fertility is limited. Obesity impairs male fertility through hormonal disruption, increased scrotal temperature, and oxidative stress. Weight loss generally improves male fertility parameters including testosterone levels and sperm quality. Animal studies have shown some effects on sperm, but human relevance is unclear. Men actively trying to conceive should discuss GLP-1 treatment with both their weight loss provider and a reproductive specialist.
Ready to take the next step?
Discuss family planning with your providerFrequently asked questions
Weight loss — including through GLP-1 — can improve fertility, especially in women with obesity-related infertility or PCOS. This is a weight loss effect, not a direct medication effect. Some women conceive unexpectedly due to restored ovulation.
Most providers recommend stopping 1-2 months before attempting conception to allow full medication clearance. Discuss your specific timeline with your provider.
Stop the medication immediately and contact your provider and obstetrician. Do not continue GLP-1 during pregnancy. Most reported cases of inadvertent GLP-1 exposure in early pregnancy have not shown adverse outcomes, but data is limited.
GLP-1 medications are generally not recommended during breastfeeding due to lack of safety data. After breastfeeding, discuss restarting with your provider. Your weight, health status, and treatment goals will inform the decision.
Want more evidence-based health research from Surfbound?